image

Issue #8 Spring 2021
atcormedical.com • 2 minute read

Welcome to VITALITY.

You’re receiving this newsletter because you’re a customer, partner, or you’ve otherwise subscribed or opted in at one of our events, conferences, or website

Summary:

  • Letter from our CEO, Craig Cooper.
  • Our half-yearly business update.
  • How central blood pressure helps manage hypertension.
  • New team additions.
  • Annoucing the winners of our smartwatch competition.

From the Heart

Thoughts from our CEO, Craig Cooper

image

With the New Year’s personal and professional resolutions underway, I am reminded that there is no replacement for hard work, persistence and dedication to achieving ones’ goals. This applies to the ATCOR team’s performance as you will see from our half-yearly report and media coverage. We are also excited to welcome new team members, including Bill Stump and others, whose skills and expertise are a valuable addition to our group.

For those looking to improve their health in 2021, I also want to share my recent article in Anti-Aging Medicine News about how central blood pressure measurement can help reduce the risk of hypertension along with medication, lifestyle, and nutritional changes.

I’m also excited to announce the five winners of our smartwatch drawing. We truly appreciate all of your support and look forward to building a healthy & prosperous 2021!

Stay healthy, stay strong,

image

Half-yearly Business Update

image

CardieX Limited, ATCOR’s parent company, shared its half-yearly report last week – continuing to deliver strong sales growth through February, and achieving the best 1H sales results in the past five years. In addition, with key new executives hires in place, new products on track for launch in 2021, and a successful Stock Purchase Program, CardieX is well-positioned to capitalize on new market opportunities. CardieX CEO, Craig Cooper, provided more detail in an interview with Proactive Australia. Watch the full interview here.

New Approaches to Managing Hypertension Using Central Blood Pressure Measurement

image

Many people think they have their blood pressure under control but still risk arterial and organ damage from a “high normal” range of 140/90 mmHg. A customized approach that combines medication, nutrition and lifestyle changes, informed by Central Aortic Blood Pressure to assess arterial stiffness, can help manage high blood pressure. Click here to read the full article in the latest Anti-Aging Medicine News, by ATCOR’s CEO, Craig Cooper.

Welcome New Team Members

image

William Stump Joins as Content + Partnership Lead

Join us in welcoming William “Bill” Stump to our team to help with our content, partnerships, and digital strategy. Bill comes to us after C-suite and executive leadership positions at Mens Health, Womens Health, Prevention Magazine, and the Rodale Inc. Media Group.

In addition, Jonathan Greene joins as a Senior Software Engineer, and Isabella Tan, joins us as a Research Assistant. We are grateful to be able to draw on each of your unique skills and knowledge!

Smartwatch Winners Announced

image

Thank you to everyone who signed up for this newsletter and a chance to win one of five of our smartwatches when they are available for limited release in June. We will be in touch with each of the winners to share the good news this week. They are: Paul K., Josh R., Stewart C., Allan C., and Phil P.

Stay tuned for more updates on the smartwatch and other products, and for more chances to win!

Get In Touch

image

We’d love to hear from you

About Us

ATCOR is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses physiological and health analytics for wearable devices for medical and consumer applications. The company’s digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients’ health (2021 launch). ATCOR is a subsidiary of CardieX Limited, which is listed on the Australian Stock Exchange (ASX:CDX).